logo

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Vincent Patrick Rocco

USPTO Granted Patents = 27

Average Co-Inventor Count = 4.9

ph-index = 8

Forward Citations = 323(Granted Patents)


Company Filing History:

goldMedal26 out of 4,446 
 
Eli Lilly and Company
 patents
silverMedal1 out of 10 
 
Eli Lilly Company
 patents

Years Active: 1996-2008

Loading Chart...
27 patents (USPTO):Explore Patents
1. 7384934 - Piperazine substituted aryl benzodiazepines (2008-06-10),
2. 7214673 - Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders (2007-05-08),
3. 7208505 - β3 adrenergic agonists (2007-04-24),
4. 7144898 - Indole derivatives for the treatment of depression and anxiety (2006-12-05),
5. 7087635 - 3-substituted oxindole β3 agonists (2006-08-08),
6. 6911463 - 3-substituted oxindole β-3 agonists (2005-06-28),
7. 6844344 - Benzofuran derivatives (2005-01-18),
8. 6835733 - Tropane linked benzofuran derivatives (2004-12-28),
9. 6784180 - Piperidines derivatives and their use as serotonin receptor antagonists (2004-08-31),
10. 6376505 - 5-HT1A and 5-HT1D&agr;dalpha antagonists (2002-04-23),
11. 6358972 - 5-HT1F agonists (2002-03-19),
12. 6303627 - Inhibitors of serotonin reuptake (2001-10-16),
13. 6242450 - 5-HT1F antagonists (2001-06-05),
14. 6172073 - Compounds having effects on serotonin-related systems (2001-01-09),
15. 6150375 - 5.alpha.-reductase inhibitors (2000-11-21),

Title: Unveiling the Innovative Mind of Vincent Patrick Rocco

Introduction:

Vincent Patrick Rocco, a prolific inventor based in Indianapolis, IN (US), has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 27 patents. His groundbreaking work in developing Piperazine substituted aryl benzodiazepines showcases his ingenuity and dedication to advancing medical science.

Latest Patents:

Rocco's latest patents focus on compounds that have the potential to revolutionize the treatment of psychosis and bipolar disorders. These compounds, described by a complex formula, serve as potent dopamine D2 receptor antagonists, offering new hope for patients suffering from these debilitating conditions.

Career Highlights:

Throughout his career, Rocco has been associated with esteemed pharmaceutical companies such as Eli Lilly and Company. His tenure at these renowned organizations has provided him with the platform to translate his innovative ideas into tangible solutions that have the power to transform healthcare landscapes.

Collaborations:

Rocco has had the privilege of collaborating with accomplished professionals in the field, including James E Audia and John M Schaus. These collaborative efforts have not only enriched his own understanding but have also led to the development of groundbreaking inventions that have the potential to impact countless lives.

Conclusion:

In conclusion, Vincent Patrick Rocco's unwavering commitment to innovation and his relentless pursuit of excellence have cemented his legacy as a pioneering inventor in the pharmaceutical industry. His latest patents stand as a testament to his visionary approach and his dedication to making a meaningful difference in the world of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…